

---

# Drug Discovery and Evaluation: Pharmacological Assays



---

Franz J. Hock  
Editor

# Drug Discovery and Evaluation: Pharmacological Assays

Fourth Edition

With 26 Figures and 28 Tables

 Springer Reference

*Editor*

Franz J. Hock  
CorDynamics  
Dieburg  
Germany

ISBN 978-3-319-05391-2      ISBN 978-3-319-05392-9 (eBook)  
ISBN 978-3-319-05393-6 (print and electronic bundle)  
DOI 10.1007/978-3-319-05392-9

Library of Congress Control Number: 2015951083

Springer Cham Heidelberg New York Dordrecht London  
3rd edition: © Springer-Verlag Berlin Heidelberg New York 2008  
© Springer International Publishing Switzerland 2016

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Printed on acid-free paper

Springer International Publishing AG Switzerland is part of Springer Science+Business Media (www.springer.com)

*In Memory of Hans Gerhard Vogel 1927–2011.*



---

## Preface to the Fourth Edition

The fourth edition of the book *Drug Discovery and Evaluation: Pharmacological Assays* is presented here.

The concept of the book has changed since the third edition, and we have now split the chapters for better reading and web search. The volume data has again risen considerably compared to the third edition. In particular, a large number of assays and new topics have been added.

Several chapters are new, and most of the chapters have been revised and have been thoroughly updated as well. I am indebted to my colleagues rewriting and updating the chapters and I also thank the authors who provided new topics for this book.

The approach to drug discovery has changed continuously during recent years. Decades ago, most of the drugs were found by serendipity in clinical trials. New drugs, however, were found in animal experiments by a classical approach. This classical approach has advantages and disadvantages. The main advantage was the relatively high predictability of success. The major disadvantage was that we got little or no information about the molecular mechanisms involved in the observed effects. New mechanisms always required new models.

The costs of developing new drugs are exploding, while the output is decreasing. A change in paradigm, the target-based or mechanism-based drug discovery approach, was welcomed with great enthusiasm. Combinatorial chemistry could generate thousands of new compounds. They were tested in high-throughput systems. This made it highly effective for the identification of target-selective compounds. Although this technique showed very great advantages from a scientific and practical viewpoint, it did not translate into higher success rates. The target-based approach has therefore been replaced again by the physiology-based approach – the classical drug discovery – or the function-based approach, which seeks to induce a therapeutic effect by normalizing a disease-specific abnormality.

I am aware that the rapid progress in biology will once again change the methodological approaches in the coming years. In addition, electronic media will continuously help scientists to access and share information. However, on the other hand, it is becoming more and more evident that many young pharmacologists have only limited training in classical pharmacological methods. When searching for these classical methods, researchers will find only insufficient information on the methodological details in electronic

databases. To this end, I hope the current book may bridge this gap by comprehensively covering those classical pharmacological methods, sometimes utilized for over 100 years, with modern pharmacological methods.

At this point, I would like again to express my sincere thanks to all colleagues who contributed to the new edition of this book. Their names and affiliations are given in alphabetical order.

A special thanks goes to Hans Gerhard Vogel, who was the Editor-in-Chief of the first three editions. He was furthermore the initiator of the *Drug Discovery and Evaluation* titles at Springer consisting of *Pharmacological Assays*, *Safety and Pharmacokinetic Assays*, and *Methods in Clinical Pharmacology*. Gerhard Vogel passed away in 2011. Personally, I am personally very much indebted to him. He introduced me to pharmacology and was always my mentor thereafter. It is an honor to continue his work.

Autumn  
2015

Franz J. Hock



---

# Contents

## Volume 1

<b>Part I Cardiovascular Activity</b> .....	<b>1</b>
<b>Studies in Isolated Organs</b> .....	<b>3</b>
Michael Gralinski, Liomar A.A. Neves, and Olga Tiniakova	
<b>Cardiovascular Analysis In Vivo</b> .....	<b>41</b>
Michael Gralinski, Liomar A.A. Neves, and Olga Tiniakova	
<b>Methods to Induce Experimental Hypertension</b> .....	<b>135</b>
Michael Gralinski, Liomar A.A. Neves, and Olga Tiniakova	
<b>Coronary Drugs</b> .....	<b>165</b>
Michael Gralinski, Liomar A.A. Neves, and Olga Tiniakova	
<b>Calcium Uptake Inhibition Activity</b> .....	<b>217</b>
Michael Gralinski, Liomar A.A. Neves, and Olga Tiniakova	
<b>Anti-Arrhythmic Activity</b> .....	<b>237</b>
Michael Gralinski, Liomar A.A. Neves, and Olga Tiniakova	
<b>Methods to Induce Cardiac Hypertrophy and Insufficiency</b> .....	<b>287</b>
Michael Gralinski, Liomar A.A. Neves, and Olga Tiniakova	
<b>Positive Inotropic Activity (Cardiac Glycosides)</b> .....	<b>335</b>
Michael Gralinski, Liomar A.A. Neves, and Olga Tiniakova	
<b>Effects on Blood Supply and on Arterial and Venous Tonus</b> .....	<b>349</b>
Michael Gralinski, Liomar A.A. Neves, and Olga Tiniakova	
<b><math>\alpha</math>- and <math>\beta</math>-Adrenoreceptor Binding</b> .....	<b>429</b>
Michael Gralinski, Liomar A.A. Neves, and Olga Tiniakova	
<b>Adenosine Receptor</b> .....	<b>473</b>
Michael Gralinski, Liomar A.A. Neves, and Olga Tiniakova	
<b>Different Channels</b> .....	<b>497</b>
Liomar A.A. Neves and Olga Tiniakova	
<b>Effect of Different Peptides</b> .....	<b>513</b>
Michael Gralinski, Liomar A.A. Neves, and Olga Tiniakova	

<b>Na<sup>+</sup>/H<sup>+</sup> Exchange</b> .....	555
Michael Gralinski, Liomar A.A. Neves, and Olga Tiniakova	
<b>NO Activity and Rho Kinase Activity</b> .....	567
Michael Gralinski, Liomar A.A. Neves, and Olga Tiniakova	
<b>PAF Binding and Endothelins Activity</b> .....	587
Michael Gralinski, Liomar A.A. Neves, and Olga Tiniakova	
<b>Patch-Clamp and Voltage-Clamp Techniques</b> .....	611
Michael Gralinski, Liomar A.A. Neves, and Olga Tiniakova	
<b>Phosphodiesterases and the Effects of Forskolin</b> .....	645
Michael Gralinski, Liomar A.A. Neves, and Olga Tiniakova	
<b>Renin–Angiotensin System</b> .....	665
Michael Gralinski, Liomar A.A. Neves, and Olga Tiniakova	
<b>Part II Pharmacological Assays in Thrombosis and Haemostasis</b> .....	<b>709</b>
<b>In Vitro Models of Thrombosis</b> .....	711
Shaker A. Mousa	
<b>In Vivo or Ex Vivo Models of Thrombosis</b> .....	721
Shaker A. Mousa	
<b>In Vitro and Ex Vivo Tests of Coagulation and Platelet Function</b> .....	759
Shaker A. Mousa	
<b>Hemostasis Models: Bleeding Models</b> .....	783
Shaker A. Mousa	
<b>Genetic Models of Hemostasis and Thrombosis</b> .....	789
Shaker A. Mousa	
<b>Critical Issues in Experimental Models</b> .....	809
Shaker A. Mousa	
<b>Advances in Anticoagulants</b> .....	819
Shaker A. Mousa	
<b>Advances in Antiplatelets</b> .....	827
Shaker A. Mousa	
<b>Part III Activity in Urinary Tract</b> .....	<b>833</b>
<b>Diuretic and Saluretic Activity</b> .....	835
Susan Emeigh Hart	
<b>Assessment of Renal Function</b> .....	843
Susan Emeigh Hart	

---

<b>Impaired Renal Function</b> .....	881
Susan Emeigh Hart	
<b>Uricosuric and Hypo-Uricemic Activity</b> .....	901
Susan Emeigh Hart	
<b>Drug Influence on Lower Urinary Tract</b> .....	911
Susan Emeigh Hart	
<b>Part IV Respiratory Activity</b> .....	<b>931</b>
<b>Effects of Drugs on Air Ways</b> .....	933
Kristy D. Bruse	
<b>Antitussive Activity</b> .....	1001
Kristy D. Bruse	
<b>Effects on Tracheal Cells and Bronchial Mucus Secretion</b> .....	1011
Kristy D. Bruse	
<b>Binding Tests in Respiratory System</b> .....	1029
Kristy D. Bruse	
<b>Volume 2</b>	
<b>Part V Psychotropic and Neurotropic Activity</b> .....	<b>1037</b>
<b>Effects on Behavior and Muscle Coordination</b> .....	1039
Mary Jeanne Kallman	
<b>Tests for Anxiolytic Activity</b> .....	1069
Mary Jeanne Kallman	
<b>Anti-Epileptic Activity</b> .....	1215
Mary Jeanne Kallman	
<b>Hypnotic Activity</b> .....	1307
Mary Jeanne Kallman	
<b>Neuroleptic Activity</b> .....	1317
Mary Jeanne Kallman	
<b>Antidepressant Activity</b> .....	1429
Mary Jeanne Kallman	
<b>Anti-Parkinson Activity</b> .....	1515
Mary Jeanne Kallman	
<b>Animal Models of Neurological Disorders</b> .....	1553
Mary Jeanne Kallman	
<b>General Anesthetics</b> .....	1593
Mary Jeanne Kallman	

---

<b>NMRI Methods in Psychoneuropharmacology</b> .....	1609
Mary Jeanne Kallman	
<b>Part VI Drug Effects on Learning and Memory</b> .....	1625
<b>Behavioral Methods Used in the Study of Learning and Memory</b> .....	1627
F. Scott Hall and Yasir Saber	
<b>Non-behavioral Methods Used in the Study of Learning and Memory</b> .....	1675
F. Scott Hall	
<b>Part VII Effects on Peripheral Nervous System</b> .....	1715
<b>Local Anesthetic Activity</b> .....	1717
Hans-Peter Hartung	
<b>Neuromuscular Blocking Activity</b> .....	1767
Hans-Peter Hartung	
<b>Part VIII Analgesic, Anti-Inflammatory and Anti-Pyretic Activity</b> .....	1783
<b>Central Analgesic Activity</b> .....	1785
Vino Daniel	
<b>Peripheral Analgesic Activity</b> .....	1875
Vino Daniel	
<b>Anti-Inflammatory Activity</b> .....	1905
Vino Daniel	
<b>Anti-Pyretic Activity</b> .....	2025
Vino Daniel	
<b>Part IX Antiarthrotic and Immunomodulatory Activity</b> .....	2031
<b>Antiarthrotic Activity</b> .....	2033
Hans Gerhard Vogel and Martin Braddock	
<b>Methods for Testing Immunological Factors</b> .....	2091
Martin Braddock	
<b>Volume 3</b>	
<b>Part X Anti-Artheroslerotic Activity</b> .....	2205
<b>Induction of Experimental Atherosclerosis</b> .....	2207
Stefan Offermanns	

---

<b>Influence of Lipid Metabolism</b> .....	2227
Philippe Boucher and Hans Gerhard Vogel	
<b>Inhibition of Cholesterol Biosynthesis</b> .....	2247
Philippe Boucher and Hans Gerhard Vogel	
<b>Inhibition of Cholesterol Absorption</b> .....	2273
Philippe Boucher and Hans Gerhard Vogel	
<b>Interruption of Bile Acid Recirculation</b> .....	2283
Philippe Boucher and Hans Gerhard Vogel	
<b>Inhibition of Lipid Oxidation</b> .....	2285
Philippe Boucher and Hans Gerhard Vogel	
<b>Internalization of Labeled LDL into HepG2 Cells</b> .....	2291
Philippe Boucher and Hans Gerhard Vogel	
<b>Influence of Peroxisome Proliferator-Activated Receptors (PPARs) and Liver X Receptors (LXRs) on Development of Artherosclerosis</b> .....	2295
Philippe Boucher and Hans Gerhard Vogel	
<b>Part XI Activity on the Gastrointestinal Tract</b> .....	<b>2323</b>
<b>Test on Salivary Glands</b> .....	2325
Andreas W. Herling	
<b>Tests on Esophagus</b> .....	2329
Andreas W. Herling	
<b>Pharmacological Effects on Gastric Function</b> .....	2341
Andreas W. Herling	
<b>Pharmacological Effects on Intestinal Functions</b> .....	2415
Andreas W. Herling	
<b>Emetic and Anti-Emetic Activity</b> .....	2469
Andreas W. Herling	
<b>Gall Bladder Function</b> .....	2479
Andreas W. Herling	
<b>Pancreatic Function</b> .....	2497
Andreas W. Herling	
<b>Liver Function</b> .....	2547
Andreas W. Herling	
<b>Part XII Antidiabetic Activity</b> .....	<b>2567</b>
<b>Methods to Induce Experimental Diabetes Mellitus</b> .....	2569
Günter Müller	

<b>Genetically Diabetic Animals</b> .....	2583
Günter Müller	
<b>Measurement of Blood Glucose-Lowering and Antidiabetic Activity</b> .....	2623
Günter Müller	
<b>Measurement of Insulin and Other Glucose-Regulating Peptide Hormones</b> .....	2657
Günter Müller	
<b>Insulin Target Tissues and Cells</b> .....	2681
Günter Müller	
<b>Assays for Insulin and Insulin-Like Metabolic Activity Based on Hepatocytes, Myocytes and Diaphragms</b> .....	2723
Günter Müller	
<b>Assays for Insulin and Insulin-Like Activity Based on Adipocytes</b> .....	2781
Günter Müller	
<b>Assays for Insulin and Insulin-Like Regulation of Energy Metabolism</b> .....	2871
Günter Müller	
<b>Assays for Insulin and Insulin-Like Regulation of Gene and Protein Expression</b> .....	2895
Günter Müller	
<b>Assays for Insulin and Insulin-Like Signal Transduction Based on Adipocytes, Hepatocytes and Myocytes</b> .....	2935
Günter Müller	
<b>Assays for the Expression and Release of Insulin and Glucose-Regulating Peptide Hormones from Pancreatic <math>\beta</math>-Cell</b> .....	3029
Günter Müller	
<b>Measurement of Glucose Absorption</b> .....	3059
Günter Müller	
<b>Monitoring of Diabetic Late Complication</b> .....	3071
Günter Müller	
<b>Insulin Analogs: Assessment of Insulin Mitogenicity and IGF-I Activity</b> .....	3119
Günter Müller	
<b>Personalized Diagnosis and Therapy</b> .....	3167
Günter Müller	

**Volume 4**

<b>Part XIII Anti-Obesity Activity</b> .....	<b>3285</b>
<b>Methods to Induce Experimental Obesity</b> .....	3287
Andreas W. Herling	
<b>Genetically Obese Animals</b> .....	3301
Andreas W. Herling	
<b>Assays of Anti-Obesity Activity</b> .....	3319
Andreas W. Herling	
<b>Assays of Obesity-Regulating Peptide Hormones</b> .....	3341
Andreas W. Herling	
<b>Part XIV Endocrinology</b> .....	<b>3391</b>
<b>Adrenal Steroid Hormones</b> .....	3393
Jürgen Sandow	
<b>Ovarian Hormones</b> .....	3441
Jürgen Sandow	
<b>Testicular Steroid Hormones</b> .....	3477
Jürgen Sandow	
<b>Thyroid Hormones</b> .....	3501
Jürgen Sandow	
<b>Parathyroid Hormones</b> .....	3523
Jürgen Sandow	
<b>Anterior Pituitary Hormones</b> .....	3539
Jürgen Sandow	
<b>Posterior Pituitary Hormones</b> .....	3605
Jürgen Sandow	
<b>Hypothalamic Hormones</b> .....	3627
Jürgen Sandow	
<b>Effects on Different Peptide Hormones</b> .....	3691
Jürgen Sandow	
<b>Part XV Ophthalmologic Activity</b> .....	<b>3747</b>
<b>Intraocular Pressure</b> .....	3749
Beat P. Mertz	
<b>Aqueous Humor Flow Rate</b> .....	3753
Beat P. Mertz	

<b>Experimental Glaucoma</b> .....	3759
Beat P. Mertz	
<b>Local Anesthesia of the Cornea</b> .....	3771
Beat P. Mertz	
<b>Experimental Cataract Formation</b> .....	3779
Beat P. Mertz	
<b>Models on Eye Inflammation</b> .....	3785
Beat P. Mertz	
<b>Part XVI Acoustic Activity</b> .....	<b>3789</b>
<b>Pharmacologic Intervention for Acquired Hearing Loss:</b>	
<b>Assays of Drug-Induced Inner Ear Damage</b> .....	3791
Michael J. Brenner, Amrita Ray, and Jochen Schacht	
<b>Neurobiology and Pharmacology of Sleep Disorders in</b>	
<b>Otolaryngology: Head and Neck Surgery</b> .....	3801
Amrita Ray and Michael J. Brenner	
<b>Experimental Models for Drug Evaluation in</b>	
<b>Noise-Induced Hearing Loss and Age-Related Hearing</b>	
<b>Impairment</b> .....	3829
Amrita Ray, Jochen Schacht, and Michael J. Brenner	
<b>Part XVII Pharmacological Methods in Dermatology</b> .....	<b>3843</b>
<b>Skin Sensitization Testing</b> .....	3845
Hans Gerhard Vogel	
<b>Experimental Dermatitis</b> .....	3851
Howard Maibach	
<b>Pruritus Models</b> .....	3871
Howard Maibach	
<b>Psoriasis Models</b> .....	3879
Howard Maibach	
<b>Scleroderma Models</b> .....	3907
Howard Maibach	
<b>Pemphigus Models</b> .....	3913
Howard Maibach	
<b>Ichthyosis Models</b> .....	3917
Howard Maibach	
<b>Xeroderma Models</b> .....	3921
Howard Maibach	



<b>Vitiligo Models</b> .....	3925
Howard Maibach	
<b>Erythropoietic Protoporphyrria</b> .....	3929
Howard Maibach	
<b>Acne Models</b> .....	3935
Howard Maibach	
<b>Skin Mycosis</b> .....	3955
Howard Maibach	
<b>Biomechanics of Skin</b> .....	3961
Howard Maibach	
<b>Protection Against UV Light</b> .....	3995
Howard Maibach	
<b>Transepidermal Water Loss</b> .....	3999
Howard Maibach	
<b>Skin Hydration</b> .....	4003
Howard Maibach	
<b>Influence on Hair Growth</b> .....	4005
Howard Maibach	
<b>Cutaneous Microcirculation</b> .....	4009
Howard Maibach	
<b>Isolated Perfused Skin Flap</b> .....	4013
Howard Maibach	
<b>Part XVIII Functional Food</b> .....	<b>4017</b>
<b>Overview of What Functional Foods Are</b> .....	4019
Bobbie Bradford	
<b>Regulation of Functional Foods and Ingredients</b> .....	4023
Bobbie Bradford	
<b>Benefit Claims of Functional Food</b> .....	4029
Bobbie Bradford	
<b>Safety Assessment of Functional Food</b> .....	4035
Bobbie Bradford	
<b>History of Safe Use</b> .....	4043
Bobbie Bradford	
<b>Post Launch Monitoring</b> .....	4047
Bobbie Bradford	
<b>Impact of Functionality on Safety Risk Assessment</b> .....	4049
Bobbie Bradford	

---

<b>Part XIX Miscellaneous</b> .....	<b>4051</b>
<b>Orphan Drugs</b> .....	4053
Maurizio Scarpa, Cinzia Bellettato, and Christina Lampe	
<b>Zebrafish</b> .....	4071
Jason Rihel and Marcus Ghosh	
<b>Oncology Activity</b> .....	4157
Jason H. Gill and Steven D. Shnyder	
<b>Stem Cells</b> .....	4201
Benedikt Müller and Suzanne Kadereit	
<b>Quantitative Metabolomics</b> .....	4221
Amrita Cheema and Siddheshwar Chauthe	
<b>Quantitative Glycoproteomics</b> .....	4231
Radoslav Goldman	
<b>Personalized Medicine</b> .....	4235
Peggy Peissig, Anne Nikolai, Ingrid Glurich, and Murray Brilliant	
<b>Herbal Medicine</b> .....	4251
Jufeng Wang, Fanghua Huang, and Wei Li	
<b>Part XX Guidelines for the Care and Use of Laboratory Animals</b> .....	<b>4259</b>
<b>Regulations for the Care and Use of Laboratory Animals in Various Countries</b> .....	4261
Andreas W. Herling	
<b>Techniques of Blood Collection in Laboratory Animals</b> .....	4263
Andreas W. Herling	
<b>Anesthesia of Experimental Animals</b> .....	4269
Andreas W. Herling	
<b>Euthanasia of Experimental Animals</b> .....	4277
Andreas W. Herling	
<b>Index</b> .....	4281

---

## About the Editor



**Franz Jakob Hock** Since retiring from Aventis in 2002, Dr. Hock has leveraged his experience as a freelance consultant specializing in Safety Pharmacology. Dr. Hock was a research scientist at Hoechst, Hoechst Marion Roussel, and Aventis from 1976 to 2002. He initially worked on methods in general pharmacology and nephrology, before becoming Head of a Laboratory devoted to pharmacological methods for drugs influencing memory and learning. He was ultimately Head of Laboratory for General/Safety

Pharmacology at the Frankfurt site of Aventis Pharma Deutschland GmbH.

Dr. Hock received his MSc in Neurobiology from the Technical University Darmstadt and his D.Sc. in Zoology from the University Kassel, Department of Biology, Institute of Neuroethology and Biocybernetics.

He received the degree of Fachpharmakologe DGPT (“certified expert pharmacology”) in 1981. In 1983, he spent a sabbatical year at the University of California, Irvine, at the Center for the Neurobiology of Learning and Memory (Director Prof. Dr. James L. McGaugh).

He lectured for several years to students of Biology at the University of Kassel and the Technical University of Darmstadt. He has published over 100 original papers on methods in pharmacology and on new compounds. Furthermore, he held 28 patent applications to protect or broaden the application of lead structures.

He is currently a member of the Task Force General/Safety Pharmacology German/Swiss Pharmaceutical Companies. A member of several national and international scientific societies, Dr. Hock is a founding member of “Safety Pharmacology Society,” “Neurowissenschaftliche Gesellschaft e.V.,” and “European Behavioural Pharmacology Society.” For several years, he served as a member of the Program Committee of the Safety Pharmacology Society. He is a member of several domestic and international scientific societies.



---

## Contributors

**Cinzia Bellettato** Brains for Brain Foundation, Padova, Italy

**Philippe Boucher** Department of Physiology, Université de Strasbourg, UMR CNRS 7213, Illkirch Cedex, France

**Martin Braddock** Global Medicines Development Respiratory Projects, AstraZeneca R&D, Cheshire, England, UK

**Bobbie Bradford** Unilever, Milton Keynes, UK

**Michael J. Brenner** Kresge Hearing Research Institute, University of Michigan, Ann Arbor, MI, USA

**Murray Brilliant** Marshfield Clinic, Marshfield, WI, USA

**Kristy D. Bruse** Integrated Physiology and Pharmacology Consulting, LLC, Poughkeepsie, NY, USA

**Siddheshwar Chauthe** Waters Center of Innovation for Metabolomics, Georgetown University Medical Center, Washington, DC, USA

**Amrita Cheema** Departments of Oncology and Biochemistry, Molecular and Cellular Biology, Georgetown University Medical Center, Washington, DC, USA

**Vino Daniel** Pfizer Inc, New Jersey, USA

**Marcus Ghosh** Department of Cell and Developmental Biology, University College London, London, UK

**Jason H. Gill** School of Medicine, Pharmacy and Health, Durham University, Stockton-on-Tees, UK

**Ingrid Glurich** Marshfield Clinic, Marshfield, WI, USA

**Radoslav Goldman** Georgetown University Hospital, Georgetown Lombardi, Washington, DC, USA

**Michael Gralinski** CorDynamics, Inc., Chicago, IL, USA

**F. Scott Hall** College of Pharmacy and Pharmaceutical Sciences, Frederic and Mary Wolfe Center, Pharmacology Department, MS-1015, The University of Toledo, HSC, Toledo, OH, USA

**Susan Emeigh Hart** Non-Clinical Drug Safety, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA

**Hans-Peter Hartung** Neurologische Klinik, Heinrich-Heine Universität, Düsseldorf, Germany

**Andreas W. Herling** Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany

**Fanghua Huang** Center for Drug Evaluation, CFDA, Beijing, China

**Suzanne Kadereit** Faculty of Life Sciences, Albstadt-Sigmaringen University, Sigmaringen, Germany

**Mary Jeanne Kallman** Kallman Preclinical Consulting, Greenfield, IN, USA

**Christina Lampe** Center of Rare Diseases, Horst Schmidt Klinik, Wiesbaden, Germany

Brains for Brain Foundation, Padova, Italy

**Wei Li** National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing, China

**Howard Maibach** Department of Dermatology, UC San Francisco, San Francisco, CA, USA

**Beat P. Mertz** SD Pharma Solutions Inc., Victoria, BC, Canada

**Shaker A. Mousa** The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USA

**Benedikt Müller** Faculty of Life Sciences, Albstadt-Sigmaringen University, Sigmaringen, Germany

**Günter Müller** Helmholtz Center Munich, Institute for Diabetes and Obesity, Munich, Germany

**Liomar A. A. Neves** CorDynamics, Inc., Chicago, IL, USA

**Anne Nikolai** Marshfield Clinic, Marshfield, WI, USA

**Stefan Offermanns** Abteilung Pharmakologie, Max-Planck-Institut für Herz- und Lungenforschung, Bad Nauheim, Germany

**Peggy Peissig** Marshfield Clinic, Marshfield, WI, USA

**Amrita Ray** Kresge Hearing Research Institute, University of Michigan, Ann Arbor, MI, USA

**Jason Rihel** Department of Cell and Developmental Biology, University College London, London, UK

**Yasir Saber** College of Pharmacy and Pharmaceutical Sciences, Frederic and Mary Wolfe Center, Pharmacology Department, MS-1015, The University of Toledo, HSC, Toledo, OH, USA

**Jürgen Sandow** An der Linde 2, Glashütten, Germany

**Maurizio Scarpa** Center of Rare Diseases, Horst Schmidt Klinik, Wiesbaden, Germany

Department of Pediatrics, University of Padova, Padova, Italy

Brains for Brain Foundation, Padova, Italy

**Jochen Schacht** Department of Biological Chemistry, Kresge Hearing Research Institute, University of Michigan, Ann Arbor, MI, USA

**Steven D. Shnyder** Institute of Cancer Therapeutics, University of Bradford, Bradford, UK

**Olga Tiniakova** CorDynamics, Inc., Chicago, IL, USA

**Hans Gerhard Vogel** Aalen, Germany

**Jufeng Wang** National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing, China